Arg257Cys polymorphism of CYP2A13 in a Chinese population

Clinica Chimica Acta

Volumn 343, Issue 1-2, 2004, Pages 213-216

  Cheng, Xin Yuan ^a   Chen, Guo Lin ^a   Zhang, Wei Xia ^a   Zhou, Gan ^a   Wang, Dan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chinese; CYP2A13; Cytochrome P450; Genetic polymorphism; Genotype

Indexed keywords

ARGININE DERIVATIVE; CYSTEINE DERIVATIVE; CYTOCHROME P450 2A;

ALLELE; ARTICLE; CHINA; CONTROLLED STUDY; CYTOCHROME P450 2A13 GENE; EXON; GENE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MOLECULAR BIOLOGY; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ALLELES; ARGININE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYSTEINE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

NICOTIANA TABACUM;

EID: 2042507725     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.01.017     Document Type: Article

References (15)

1. Fernandez-Salguero P., Hoffman S.M., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660
2. Zhang X.L., Su T., Zhang Q.Y., Gu J., Caggana M., Li H.M., et al. Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J. Pharmacol. Exp. Ther. 302:2002;416-423
3. Fernandez-Salguero P., Gonzalez F.J. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics. 5:1995;S123-S128
4. Thornton-Manning J.R., Nikula K.J., Hotchkiss J.A., Avila K.J., Rohrbacher K.D., Ding X., et al. Nasal cytochrome P450 2A: identification, regional localization, and metabolic activity toward hexamethylphosphoramide, a known nasal carcinogen. Toxicol. Appl. Pharmacol. 142:1997;22-30
5. Liu C., Zhuo X., Gonzalez F.J., Ding X. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants. Mol. Pharmacol. 50:1996;781-788
6. Patten C.J., Smith T.J., Friesen M.J., Tynes R.E., Yang C.S., Murphy S.E. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N′-nitrosonornicotine α-hydroxylation by human liver microsomes. Carcinogenesis (Lond.). 18:1997;1623-1630
7. Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261:1999;658-660
8. Su T., Bao Z.P., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl) -1-butanone. Cancer Res. 60:2000;5074-5079
9. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91:1999;1194-1210
10. Hecht S.S. Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11:1998;559-603
11. Hecht S.S. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. Proc. Soc. Exp. Biol. Med. 216:1997;181-191
12. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. 1989;16-19 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
13. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267:1992;83-90
14. Hasemann C.A., Kurumbail R.G., Boddupalli S.S., Peterson J.A., Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure. 3:1995;41-62
15. Meyer U.A. Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics. 1:1991;66-67